ECSP014106A - Interleuquina 2 estabilizada - Google Patents

Interleuquina 2 estabilizada

Info

Publication number
ECSP014106A
ECSP014106A EC2001004106A ECSP014106A ECSP014106A EC SP014106 A ECSP014106 A EC SP014106A EC 2001004106 A EC2001004106 A EC 2001004106A EC SP014106 A ECSP014106 A EC SP014106A EC SP014106 A ECSP014106 A EC SP014106A
Authority
EC
Ecuador
Prior art keywords
interleuquina
stabilized
variant
preferred formulation
reconstitution
Prior art date
Application number
EC2001004106A
Other languages
English (en)
Inventor
Weibo Wang
Michael Shearer
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP014106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP014106A publication Critical patent/ECSP014106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una preparación farmacéutica estable que comprende interleuquina-2 humana o una variante de la misma y una cantidad estabilizante de histidina una formulación preferida incluye glicina y sacarosa y una variante de II-2 que tiene una mutación simple, N88R. La formulación preferida es en forma leofilizada que con la reconstitución con un diluyente acuoso, produce una solución que tiene un ph que varia desde aproximadamente 5,0 a 6,5.
EC2001004106A 2000-06-28 2001-06-27 Interleuquina 2 estabilizada ECSP014106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2

Publications (1)

Publication Number Publication Date
ECSP014106A true ECSP014106A (es) 2002-02-25

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004106A ECSP014106A (es) 2000-06-28 2001-06-27 Interleuquina 2 estabilizada

Country Status (24)

Country Link
US (1) US6689353B1 (es)
EP (1) EP1370280B1 (es)
JP (3) JP5522878B2 (es)
KR (1) KR100799402B1 (es)
CN (1) CN1523997B (es)
AR (1) AR029139A1 (es)
AU (1) AU2001273063A1 (es)
BR (1) BR0112101B1 (es)
CA (1) CA2413334C (es)
CO (1) CO5290308A1 (es)
CU (1) CU23536A3 (es)
DE (1) DE60142412D1 (es)
DO (1) DOP2001000197A (es)
EC (1) ECSP014106A (es)
ES (1) ES2344729T3 (es)
HN (1) HN2001000139A (es)
IL (2) IL153587A0 (es)
MX (1) MXPA03000046A (es)
MY (1) MY128629A (es)
PE (1) PE20020127A1 (es)
SV (1) SV2002000512A (es)
TW (1) TWI235063B (es)
UY (1) UY26805A1 (es)
WO (1) WO2002000243A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
WO2005113147A2 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
KR20070110901A (ko) 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CA2761675A1 (en) * 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
CN103063829B (zh) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 一种冻存液
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12565525B2 (en) 2018-03-28 2026-03-03 Ascendis Pharma Oncology Division A/S IL-2 conjugates
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
PE20221506A1 (es) 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230398183A1 (en) * 2020-11-13 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPS60215631A (ja) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
JPH0229016A (ja) * 1989-06-09 1990-01-31 Alpine Electron Inc イコライザ装置
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6509023B1 (en) * 1997-07-31 2003-01-21 Rhodia Chimie Cosmetic composition comprising a functionalized polyorganosiloxane
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
BR0112101A (pt) 2004-07-06
JP5989728B2 (ja) 2016-09-07
JP2004532791A (ja) 2004-10-28
MXPA03000046A (es) 2003-06-19
PE20020127A1 (es) 2002-04-27
DE60142412D1 (de) 2010-07-29
AU2001273063A1 (en) 2002-01-08
KR20030016312A (ko) 2003-02-26
CA2413334A1 (en) 2002-01-03
CA2413334C (en) 2011-03-08
WO2002000243A2 (en) 2002-01-03
KR100799402B1 (ko) 2008-01-30
CN1523997B (zh) 2010-09-01
BR0112101B1 (pt) 2017-11-14
IL153587A (en) 2007-12-03
MY128629A (en) 2007-02-28
IL153587A0 (en) 2003-07-06
CO5290308A1 (es) 2003-06-27
CU23536A3 (es) 2010-06-17
SV2002000512A (es) 2002-07-03
JP2012211166A (ja) 2012-11-01
UY26805A1 (es) 2002-01-31
US6689353B1 (en) 2004-02-10
EP1370280B1 (en) 2010-06-16
AR029139A1 (es) 2003-06-04
TWI235063B (en) 2005-07-01
WO2002000243A3 (en) 2003-10-02
CN1523997A (zh) 2004-08-25
HN2001000139A (es) 2003-12-11
ES2344729T3 (es) 2010-09-06
JP5522878B2 (ja) 2014-06-18
EP1370280A2 (en) 2003-12-17
DOP2001000197A (es) 2003-01-15
JP2015007114A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
AR029139A1 (es) Interleuquina 2 estabilizada
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
EP1246608A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE ADMINISTRATION OF MEDICAMENTS HAVING A LOW AQUEOUS SOLUBILITY
DE69810481D1 (de) Stabilisierte antikörperformulierung
IT1240314B (it) Formulazioni acquose stabilizzate di piccoli peptidi.
ATE205090T1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
PT814782E (pt) Composicao farmaceutica estabilizada com um agente basico
EP1314437A4 (en) ANTIBODY-CONTAINING STABILIZED PREPARATIONS
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
ATE218364T1 (de) Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
NO996323L (no) Medisinske blandinger for anvendelse på mukosa
ATE244029T1 (de) Pharmazeutische ampulle
DK1112060T3 (da) Doseringsform anvendende flydende formulering
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
ATE264340T1 (de) Stabilisierung von gefriergetrocknetem kuchen
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
ATE258046T1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
ITRM20010731A1 (it) Procedimento per la produzione di emulsioni acquose stabili di sostanze lipofile di interesse farmaceutico ed emulsioni cosi' ottenute.
MX9707121A (es) Formulaciones liquidas de gch.